Bioliberty Raises €2.95M to Extend Home Rehabilitation
Bioliberty raised €2.95M Series A extension to extend its AI-powered rehabilitation technology into the home environment.
The big picture: Bioliberty, an Edinburgh- and Boston-based rehabilitation technology startup, has raised a €2.95 million ($3.3 million) Series A extension, bringing its total funding to €12.07 million ($13.5 million). The round adds four new institutional backers: TGH Ventures, Ballad Ventures, Whiterock, and 25m Health.
Why it matters:
- Expanding Access: The funding will enable Bioliberty to extend its soft-robotic rehabilitation technology into home environments, ensuring continuity of care beyond clinical settings.
- Data Integration: The company aims to connect rehabilitation data across various care settings, creating a more holistic patient journey.
- AI Augmentation: Additional AI capabilities will be developed to further support clinical decision-making, therapy, and assessment for physical and occupational therapists.
How it works:
- Soft Robotics: Bioliberty develops soft-robotic rehabilitation technology, primarily for upper-extremity recovery in stroke patients and those with mobility-limiting neurological conditions.
- Integrated System: Its product suite includes Lifehub (a portable control center), Lifeglov (a soft robotic wearable glove for hand assistance), and Lifemind (an AI-powered clinician dashboard for data and notes).
- Clinical Efficacy: Co-developed with leading inpatient facilities, the technology facilitates quick setup and increased repetitions per session, with Lifehub and Lifeglov being FDA-listed.
The catch: The home rehabilitation market is competitive, with numerous digital health and wearable solutions vying for patient and provider adoption. Bioliberty’s success will depend on seamless integration with existing healthcare workflows, demonstrating clear cost-effectiveness, and navigating regulatory complexities for at-home medical devices, particularly in the US market where it recently launched.
Key Facts
- Company: Bioliberty
- Amount: €2.95M
- Round: Series A+
- Investors: TGH Ventures, Ballad Ventures, Whiterock, 25m Health
- Founders: Rowan Armstrong, Ross O’Hanlon, Conan Bradley, Shéa Quinn
- Announced: 2026-11-01
- Sector: Rehabilitation Robotics
- Headquarters: Edinburgh, UK
AIPressRoom Weekly
Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.